Watch for Eysuvis and Other Steroid Drops for Dry Eyes

January 2021

Rx Eysuvis (loteprednol 0.25% suspension) will be the first FDA-approved ophthalmic corticosteroid for treating dry eyes.

But it’s only for up to 2 weeks of use.

We know long-term use of any ophthalmic steroid can increase the risk of glaucoma or cataracts...regardless of the steroid, strength, or formulation.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

COVID-19 Share Answers About mRNA COVID-19 Vaccines
Dyslipidemia Don’t Rely on Omega-3s for Cardiovascular Benefits
COVID-19 Know When to Consider New COVID-19 Monoclonal Antibodies
Obesity & Weight Loss Expect Questions About Plenity for Weight Loss
Heart Failure Help Heart Failure Patients Succeed With Med Adherence
Antidepressants Ask Patients About Sexual Side Effects From Antidepressants
Dermatology Clear Up Confusion About Wrinkle Products
Sore Throat Sort Out OTCs for Sore Throat
Ophthalmology Watch for Eysuvis and Other Steroid Drops for Dry Eyes
COVID-19 Put the EUA for Baricitinib Plus Remdesivir in Perspective
New Drugs Prioritize Traditional IV Opioids Over IV Oliceridine